Comparison Between a 1L of Polyethylene Glycol+Ascorbic Acid as a Split Dose Bowel Preparation for Colonoscopy
Comparison Between a 1L of Polyethylene Glycol+Ascorbic Acid as a Split Dose Bowel Preparation for Colonoscopy: Prospective, Randomized, Parallel, Multi-center Trial
Comparison between a 1L of polyethylene glycol+ascorbic acid as a split dose and oral sulfate solution bowel preparation for colonoscopy
study design: prospective, randomized, parallel, multi-center trial in 3 hospitals in Korea ( Seoul National University hospital, Seoul National University Bundang hospital, Seoul Metropolitan Government-Seoul National University )
patient inclusion criteria
- aged 20-75 adults (out-clinic patients) scheduled for colonoscopy for any indication within the normal process of care
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Hyun Jung Lee, MD, PhD
- Phone Number: +82-2-740-3439
- Email: guswjd80@gmail.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Seoul National University Hospital
-
Contact:
- Hyun Jung Lee, MD, PhD
- Phone Number: +82-2-740-3439
- Email: guswjd80@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult out clinic patients scheduled for colonoscopy for any indication within the normal process of care
Exclusion Criteria:
- previous history of significant gastrointestinal surgeries (except for appendectomy)
- known or clinically suspicious Inflammatory bowel disease patients
- known or suspected ileus/ GI obstruction
- previous history of major cancer or currently on treating cancer
- Major cardiovascular disease, respiratory disease, liver, hematologic diseases with complication
- severe cognitive impairment / dementia / confusion state
- past history within the last 12 months or current episode of severe constipation severe constipation
- Regular use of laxatives or colon motility-altering drugs (i. e. more than 2 - 3 times per week) in the last 28 days prior to screening and/or laxative use within 72 hours prior to administration of the preparation)
- women who are pregnant or lactating
- known phenylketonuria, glucose-6-phosphate dehydrogenase deficiency
- those who were allergic to any preparation components.
- those who, in the opinion of the investigator, should not be included in the study for any reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: CleanViewAL
1L polyethylene glycol+ascorbic acid split dose
|
1L PEG + ascorbic acid bowel preparation for colonoscopy
|
|
PLACEBO_COMPARATOR: SUPREP
Oral sulfate solutiom
|
Oral sulfate solution for colonoscopy bowel preparation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Boston Bowel Preparation Scale (BBPS)
Time Frame: at the time of colonoscopy procedure
|
Bowel cleansing score
|
at the time of colonoscopy procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
questionnaire gathered for Tolerability, compliance, satisfaction
Time Frame: on the 1 day of colonoscopy via questionnaire
|
information gathered via questionnaire
|
on the 1 day of colonoscopy via questionnaire
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jong Pil Im, MD, PhD, Seoul National University Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1905-1831
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.